Equities Analysts Offer Predictions for BioLineRx Ltd.’s FY2025 Earnings (NASDAQ:BLRX)

BioLineRx Ltd. (NASDAQ:BLRX) – Stock analysts at Zacks Small Cap issued their FY2025 earnings per share (EPS) estimates for shares of BioLineRx in a report released on Thursday, September 14th. Zacks Small Cap analyst J. Vandermosten anticipates that the biotechnology company will post earnings of ($0.01) per share for the year. The consensus estimate for BioLineRx’s current full-year earnings is ($0.83) per share.

BioLineRx (NASDAQ:BLRX) last announced its quarterly earnings data on Wednesday, August 30th. The biotechnology company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.14). During the same quarter in the prior year, the company earned ($0.16) earnings per share.

Several other equities analysts also recently commented on BLRX. StockNews.com raised BioLineRx to a “sell” rating in a research report on Monday, September 4th. HC Wainwright upped their price objective on BioLineRx from $19.00 to $21.00 in a research report on Friday.

BioLineRx Stock Performance

Shares of BioLineRx stock opened at $1.76 on Friday. The stock’s fifty day moving average is $1.61 and its two-hundred day moving average is $1.35. The company has a market capitalization of $108.29 million, a PE ratio of -2.55 and a beta of 1.80. The company has a quick ratio of 2.79, a current ratio of 2.79 and a debt-to-equity ratio of 0.40. BioLineRx has a 52 week low of $0.55 and a 52 week high of $2.53.

Institutional Investors Weigh In On BioLineRx

Several hedge funds have recently made changes to their positions in the company. LPL Financial LLC lifted its holdings in shares of BioLineRx by 6.4% in the 2nd quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock worth $200,000 after buying an additional 7,500 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of BioLineRx by 49.1% in the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after buying an additional 22,478 shares during the period. Envestnet Asset Management Inc. purchased a new stake in shares of BioLineRx in the 1st quarter worth $88,000. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of BioLineRx in the 1st quarter worth $178,000. 2.01% of the stock is currently owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.